NDAORALCAPSULE
Approved
Jun 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
LYRICA (pregabalin) by Teva is 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. First approved in 2005.
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pregabalin (LYRICA) is an oral small-molecule calcium channel modulator that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It reduces pro-nociceptive neurotransmitter release in the spinal cord and modulates descending pain pathways, making it effective for neuropathic pain, fibromyalgia, and seizure disorders. The drug does not act as a GABA agonist despite structural similarity to GABA.
LOE Approaching
As a mature product approaching loss of exclusivity, LYRICA brand teams are transitioning from growth-focused roles to generic defense and lifecycle management strategies with potentially smaller commercial footprints.
Mechanism of Action
2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.